A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Francis Joseph Giles

A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Francis Joseph Giles

Medicine

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

Original language	English (Ireland)
Journal	Journal Of Clinical Oncology
Volume	28
Publication status	Published - 1 Jan 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Fisher. T., Stone, R.M., DeAngelo, D., Galinsky, I., Estey, E., Cohen, P., Fox, E., Ehninger, G., Feldman, E.J., Schiller, G.J., Klimek, V.M., Nimer, S.D., Gilliland, D.G., Wong, Y.F., Massimini, G., Giles, F.J.

Cite this

@article{35520ff279834ce7902349df65e931f2,

title = "A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.",

author = "Giles, \{Francis Joseph\}",

year = "2010",

month = jan,

day = "1",

language = "English (Ireland)",

volume = "28",

journal = "Journal Of Clinical Oncology",

}

A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. / Giles, Francis Joseph.
In: Journal Of Clinical Oncology, Vol. 28, 01.01.2010.

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

TY - JOUR

T1 - A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

AU - Giles, Francis Joseph

PY - 2010/1/1

Y1 - 2010/1/1

M3 - Article

VL - 28

JO - Journal Of Clinical Oncology

JF - Journal Of Clinical Oncology

ER -